Kyaw Thein

Assistant Professor

Oregon Health & Science University

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Kyaw Thein is an Assistant Professor at Oregon Health & Science University in the United States. His research interests focus on oncology, particularly in drug development, including histology-agnostic therapies and thromboprophylaxis in cancer patients. He has contributed to multiple systematic reviews and meta-analyses addressing the efficacy and safety of treatments in various cancer contexts.

Articles (14)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (6)

Janos Roszik

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Scott E. Kopetz

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Malinda West

Assistant Professor of Medicine

University of Wisconsin-Madison

UNITED STATES

View details

Bettzy Stephen

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Sarina Piha-Paul

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Thein Hlaing Oo

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kyaw Thein

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab

Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development

Histology Agnostic Drug Development: An Updated Review

Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions

Updated meta-analysis of randomized controlled trials on primary outpatient thromboprophylaxis in patients with gastric and gastroesophageal junction cancers receiving chemotherapy

Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer

Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?

Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with ovarian cancer receiving chemotherapy

Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study

Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors

Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with nonpancreatic gastrointestinal cancers receiving chemotherapy

Collaborators (6)

Janos Roszik

Scott E. Kopetz

Malinda West

Bettzy Stephen

Sarina Piha-Paul

Thein Hlaing Oo

Make your next move.